Herpes Zoster

Drug Rejected By FDA Advisory Committee

Published in AIDS Weekly, June 24th, 1996

The U.S. Food and Drug Administration (FDA) antiviral drug advisory committee decided against recommendation of sorivudine (Bravavir), a drug designed to treat herpes zoster in immunocompromised patients.

The committee voted 7-2 against recommendation for FDA approval, citing concerns over risks versus benefits associated with use of the antiviral agent. The committee reviewed data from Japan, where sorivudine is marketed, that showed that 26 cancer patients given sorivudine for herpes zoster while on 5-fluorouracil developed severe toxicities and that 18 of the 26 patients had died.

Bristol-Myers representatives requested orphan drug status for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry